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Abstract
Background: Atopy and rhinitis are among the factors affecting exhaled nitric oxide (FeNO) values and may
contribute to difficulties in the clinical interpretation of FeNO measurements. However, data assessing their effects
on FeNO values had never been summarized. This review aims to evaluate the effect of atopy and rhinitis in FeNO
values in otherwise healthy individuals.
Methods: A systematic review was performed in Pubmed, Scopus and ISI Web of Knowledge. A two-step selection
process was completed, and from 2357 references 19 were included. The inclusion criteria were: participants
without known diseases other than rhinitis; atopy assessement by SPT or Specific IgE; and FeNO measurements
according to ATS/ERS recommendations.
Results: The 8 articles measuring FeNO in children showed higher values in both allergic rhinitis and atopic
children when compared with healthy children. The 11 articles performed in adults observed higher FeNO in AR
patients comparatively with either healthy or atopic individuals. However, adult healthy and atopic individuals had
similar FeNO values.
Conclusions: FeNO values are higher in individuals with rhinitis and/or atopy without other health problems.
These effects are small, seem to be independent and should be further studied using multivariate models. The
effect of atopy was observed only in children. The combined effect of atopy and rhinitis produced higher FeNO
values in adults. These results support that both atopy and rhinitis should be considered when interpreting or
when defining FeNO reference values.
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Background
Exhaled nitric oxide (FeNO) is associated with asthma
[1], and with airway eosinophilia [2]. Recently, it was
suggested that FeNO production in the airways is under
the influence of Th2 cytokines, IL-4 and IL-13, responsi-
ble for induction of Inducible Nitric Oxide Synthase
(iNOS) expression in the airway epithelium, and thus
for the increase of FeNO in inflammatory disorders [3].
Many individual factors influence FeNO values. In
fact, the considerable inter-subject variability hampers
the clinical interpretation of FeNO measurements [4,5].
Two important FeNO modifiers are atopy and rhinitis
[6]. Some studies reported higher FeNO values in
patients with atopy or allergic rhinitis alone [7-9], while
others observed a relationship between elevated FeNO
values and the exacerbation of rhinitis and the number
of positive wheals on skin prick tests (SPT) [10,11].
However, results are controversial, as there are studies
that did not observe significant differences of FeNO
values in atopy or rhinitis [12-14].
The aim of this systematic review was to evaluate the
effect of atopy and rhinitis in FeNO values in otherwise
healthy individuals.
Methods
This systematic review follows the PRISMA recommen-
dations [15]. Three databases were searched: Pubmed,
Scopus and ISI Web of Knowledge. The limits used
were a) English language, b) publication date from 1990
to October 2009, and c) studies with original data. The
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The inclusion criteria were: 1) atopy assessed by Skin
Prick Tests (SPT) or specific IgE for common aeroaller-
gens; 2) online FeNO measurements, according to the
American Thoracic Society/European Respiratory Society
(ATS/ERS) recommendations [6]; 3) study participants of
at least two of the following groups: healthy, atopic, with
allergic rhinitis or non allergic rhinitis. Exclusion criteria
were 1) in vitro or animal experiments or 2) participants
with known diseases other than rhinitis, e.g. asthma
alone. A study group was defined as atopic in the pre-
sence of allergic sensitization without a medical diagnosis
of asthma and rhinitis. Study selection had two phases
(Figure 1). In Phase 1, two reviewers screened the titles
and abstracts independently. If one of the reviewers
included the abstract, it was allowed into the Phase 2. In
Phase 2, manuscripts were analyzed independently and
disagreements were discussed between reviewers
Data was extracted using an electronic form developed
by the authors. Information on characteristics of the
included studies and their samples was summarized in
tables 1 and 2 and Additional File 1 (tables S1-S2). Six
studies did not present FeNO values. Authors were con-
tacted for the FeNO data, but no answer was obtained.
Four of these studies had FeNO values comparisons and
were included, and the remaining 2 were excluded.
Two groups of studies were defined, based on the par-
ticipants’ age - less than 18 years old and adults. In each
group, the studies were divided according to the sum-
mary measure used for reporting FeNO values. Four
groups of FeNO values were defined: Allergic Rhinitis
(AR), Non-Allergic Rhinitis (NAR), Healthy and Atopic.
Values were compared in sets of 2, with a total of 6
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Databases: 
-Pubmed
-Scopus
-ISI Web of Knowledge
2357 
(after duplicates 
removed)
118
Included
2239 Excluded:
I2: 411
I3: 131
E1: 979
E2: 718
99 Excluded
No FeNO values: 2
E1: 6
E2: 2
I1: 5
I2: 45
I3: 39
Search Strategy
S1) Articles 
published since 
1990; 
S2) Articles in 
English; 
S3) Not Reviews 
nor Editorials nor 
Comments
Inclusion Criteria: 
I1) Assessment of atopy by skin prick 
test or specific Ig E for common 
aeroallergens.
I2) FeNO measured with online 
technique at 50ml/s according to ATS/
ERS recommendations.
I3) Study must include at least one 
comparison of FeNO values between two 
of the following groups healthy, allergic 
rhinitis or non allergic rhinitis or atopic 
individuals.
Exclusion Criteria:
E1) All the included patients have known 
diseases (e.g. asthma) other than 
rhinitis.
E2) Animal or in vitro testing.
Two
Independent
Reviewers
Two
Independent
Reviewers
19
Included
Methods
Figure 1 Articles selection process.
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Page 2 of 7comparisons. A ratio of FeNO values in each compari-
son is presented. One study provided results during and
off pollen season [16]. Both results were included, in
separate conditions. When data allowed it, meta-analysis
were done using Review Manager 5 (Cochrane Colla-
boration) [17] using a random effects model, due to dif-
ferences on studies methods. Results showed high
heterogeneity (I
2) and were not included for analysis
(Additional File 2, figures S1-S3).
Results
Articles search retrieved a total of 2357 references after
duplicates’ removal. In the first selection phase 2239
articles were excluded, mainly studies with patients with
known conditions other than rhinitis (Figure 1). In the
second selection phase, all full-text articles were
retrieved and analyzed. Nineteen studies were included
in the systematic review (Figure 1), in eight the partici-
pants were children and in 11 were adults. Most were
cross sectional studies (n = 16), and 3 were prospective.
Seven did not report the study setting, 8 recruited the
subjects from outpatient clinics, 2 from schools, one
from general population and another one from mills
(Table 1). Sample sizes ranged from 20 to 276 partici-
pants (Table 1). Three studies included smokers and 9
included only non-smokers individuals; the remaining 7
Table 1 Description of the sample and methods of the studies included and how Atopy and Rhinitis were assessed
Article Setting Sample
Size
‡
Age Sex
(% of men)
Classification of:
Atopic Rhinits
Aronsson,
2005
NI 43
† H: 41 (19-56);
AR: 33 (18-55)
§
11% SPT Symptoms
Berlyne,
2000
Outpatient clinics 131
† H: 36 (13);
A: 37 (12)
43% SPT NA
Cardinale,
2005
Outpatient clinics (healthy: schools) 175
† H: 10.3 (2.2);
AR: 10.1 (1.8)
29% Specific IgE/Rast; Total
IgE
Clinical
Assessment
Cibella,
2008
NI 335 12.1 (10-16)
§ 43% SPT Symptoms
Gratziou,
2008
Outpatient clinics (healthy: volunteers) 27
† H: 36 (8);
AR: 35 (10)
37% SPT Symptoms
Hervás,
2008
Outpatient clinics 90 10.8 (6-15)
§ 64% SPT Clinical
Assessment
Hung, 2007 Outpatient clinics 60 5-14
|| 47% Specific IgE Symptoms
Kosticas,
2008
Schools 219* H: 21.4 (2.3); AR: 21.8
(3.0)
52% SPT Symptoms
Malmberg,
2006
Schools 276* 11.6 (6.9-15.7)
§ 51% SPT NA
Manson,
2009
NI 20 H: 23-48;
AR: 20-49
||
20% SPT Symptoms
Marcucci,
2007
NI 41 6 -10
|| NI SPT;
Specific IgE/Rast
NA
Olin, 2004 Workers 246
† H: 44.5 (0.69); AR: 41.5
(1.51)
94% Specific IgE/Rast Symptoms
Prieto, 2002
(1)
Outpatient clinics (Healthy: schools and
volunteers)
48
† H: 28.6 (9.2); AR: 33.0
(10.5)
54% SPT Clinical
Assessment
Prieto, 2002
(2)
Outpatient clinics (Healthy: schools and
volunteers)
24
† H: 27.5 (3.3); AR: 34.9
(2.8)
33% SPT Clinical
Assessment
Profita, 2006 NI 91 H: 10 (2.4);
AR: 9.9 (2.9)
59% SPT; Specific IgE/Rast;
Total IgE
Clinical
Assessment
Rolla, 2007 Outpatient clinics 108
† 39.3 (11-75)
§ 45% SPT Symptoms
Rouhos,
2008
General Population 248
† 45 (26-61) 72% SPT NI
Saito, 2004 NI 278 10-12
|| 50% Specific IgE/Rast NA
Tanou, 2009 NI 70* H: 31.8 (5.9); AR: 32.8
(7.2)
46% SPT; Total IgE Symptoms
NI - No Information; NA: Not Applicable; A: Atopic; AR: Allergic Rhinitis; H: Healthy
* Sample includes smokers;
† Sample of non-smoker individuals;
‡See more information in Additional File 1. Age values are present as Mean (SD), otherwise
indicated.
§Mean (Range);
||Range.
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Page 3 of 7Table 2 Comparison of FeNO values between groups in the 18 studies included
Studies in Children (n = 8) Studies in Adults (n = 11)
Mean
(n = 4)
Median
(n = 2)
Values not shown
(n = 2)
Mean
(n = 3)
Median
(n = 6)
Values not shown (n = 2)
Hervás
2008
[8]
Hung
2007
[22]
Malmberg
2006 [21]
Saito
2004
[28]
Cardinale
2005 [11]
Cibella
2008
[12]
Marcucci
2007 [23]
Profita
2006
[13]
Prieto
2002
[29]
Prieto,
2002 [16]
Rolla
2007
[30]
Rouhos
2008
[31]
Kostikas
2008
[32]
Tanou
2009
[33]
Berlyne
2000
[14]
Gratziou
2008
[34]
Olin
2004
[35]
Aronsson
2005 [36]
Mansson
2009 [37]
FeNO Values
Atopic 19
(1.21)
- 14.6‡ 33.3
(1.13)
- 17.4
(5.5-
95.2)*
FeNO values
not present
§
- - - 13.2
† - - 11 (6) . 16.5
(11.3-
27.6)
FeNO values
not present
§
AR 26.3
(1.04)
24.68
(19.2)
- - 15.3
(9.4-31.0)
19.1
(5.8-
92.5)*
25.1
(5.7-
102.9)
†
DS: 63.1
(1.26) OS:
30.2(1.27)
24.5
(3.32)
23.0
(11.6-
43.6)*
17.0
(12.5-
23.0)
20.5
(12.5-
33)
- 12.5
(4.0-50.0)
31.0
(16.0-
50.5)
NAR - - - - - 12.6
(2.8-
71.8)*
- - 16.1‡ - - - - - 19.2
(14.1-
22.0)
Healthy 7.9
(0.96)
9.44
(3.97)
10.3‡ 15.1
(1.14)
5.9
(3.4-9.3)
13.1
(3.0-
71.0)*
11.2
(5.0-
31.5)
**
12.6 (1.4) 13.5
(0.9)
15.5 † 10.5
(7.0-13.0)
9.5
(8.0-
12.0)
9 (7) 3.8
(1.0-7.3)
15.8
(11.9-
21.4)
Comparison of FeNO values between
||
Atopic
and
Healthy
↑↑ - ↑↑ ↑ - ↑ -- - - - N S ( ↓)- - N S ( ↑) - NS (↑)- -
AR and
Healthy
↑↑↑ ↑↑↑ -- ↑↑↑ NS (↑) ↑ NS (↔) ↑↑ E:↑↑↑
NE:↑↑
↑↑ NR (↑) ↑↑ ↑↑ - ↑↑↑ NR
(↑↑)
NS (↔) ↑
NAR
and
Healthy
-- - - - N S ( ↓)- - - - N S ( ↑)- - - - - N R
(↑↑)
--
AR and
Atopic
↑ - - - - NS (↑) - - - - - NR (↑↑)- - - - ↑↑ --
AR and
NAR
-- - - - ↑ -- - - ↑ -- - --↑ --
Atopic
and
NAR
-- - - - N S ( ↑)- - - - - - - - - - N R ( ↓)- -
Values are presented as Mean (SD) or as Median (Interquartil Range), otherwise indicated: *Median (Range), †Mean (Range), ‡ Dispersion Measure not presented,
§The studies’ reports do not included numerical results.
||
Comparison was based in a ratio between FeNO values in each group: 1, 2 or 3 arrows means a ratio increase/decrease on FeNO values of 1,2 or 3 or more times, respectively. DS: During Season OS: Out of Season. Adult
classification was defined as a mean/median age value ≥18 years. Atopic was defined as presence of allergic sensitization without asthma and without rhinitis. All comparisons are statistically significant (p < 0.05), otherwise
indicated. NR: Statistical significance not reported. NS: Not significant.
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7studies did not report smoking status (Additional File 1,
Table S1); one of the studies with children [11] excluded
those that were exposed to tobacco smoke in the family.
Most studies used SPT to identify atopic patients
(Table 1). Rhinitis was defined based on symptoms (n =
9) or clinical assessment (n = 5) (Table 1). The defini-
tion of healthy individuals was not reported in three stu-
dies, and all the others excluded atopic individuals
(Additional File 1, Table S2).
Comparisons between defined groups were reported in
all studies, but in 4 these comparisons did not present
numerical values (Table 2). Seven articles compared
Atopic and Healthy individuals. The 3 studies performed
in adults showed no significant differences in FeNO
values, while in children, the studies showed higher
FeNO values in the atopic groups. Sixteen articles com-
pared FeNO values between Allergic Rhinitis and
Healthy individuals in a total of 17 comparisons; 12
showed significant higher values of FeNO in the AR
patients. Two studies compared Atopic and Non-Aller-
gic Rhinitis individuals: one performed in children
observed a non-significant higher in FeNO values in ato-
pic individuals, while another, with an adult population,
observed lower values. When comparing Allergic Rhini-
tis and Atopic individuals all the 4 studies (2 in chil-
dren) showed higher FENO values in allergic rhinitis; in
2 of them the values were significantly higher and in the
other the statistical significance was not reported. All
articles comparing Allergic Rhinitis and Non-Allergic
Rhinitis subjects (n = 3) showed higher FeNO values in
allergic rhinitis patients. From the three articles compar-
ing FeNO values between Non-Allergic Rhinitis indivi-
duals and Healthy ones, 2 had no significant differences,
and one showed higher values in the NAR group (Figure
2).
The collected data was insufficient for quantitative
synthesis. For each comparison, 2 to 3 studies could be
used, and 2 out of the 3 meta-analysis had high hetero-
geneity (I
2 = 100%) (Additional File 2, Figures S1-S3).
Discussion
This is the first systematic review that summarizes the
i n f l u e n c eo fA l l e r g i cR h i n i t i sa n dA t o p yo nF e N O
values. FeNO was higher in children with atopy and in
children with allergic rhinitis, when compared with chil-
dren without rhinitis, atopic or with NAR. In adults, a
similar increase was observed with AR, but FeNO values
were similar between atopic and healthy individuals.
These results are in agreement with previous non-sys-
tematic reviews on AR effect on nasal and/or exhaled
nitric oxide values [5,18]. Previous results also support
the consistent effect of atopy on FeNO values that we
Healthy Healthy
Atopic
NAR
Children Adults
AR
Atopic
NAR
AR
Upper limit of
normal FeNO
range
(children)
Upper limit of
normal FeNO
range (adults)
Figure 2 Visualization of summaries of FeNO comparisons. Groups with overlapping circles showed similar FeNO values. The radius of each
circle is proportional to the number of articles measuring FeNO in each group. Upper limit of normal FeNO range was based on previous
reports on children [21] and adults’ [20] FeNO values. Atopic was defined as presence of allergic sensitization without asthma and without
rhinitis.
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Page 5 of 7observed in healthy children; however they are not in
agreement with the absence of effect of atopy in FeNO
levels that we found in adults [5,19]. Similar values were
also observed between atopic individuals without rhinitis
and patients with NAR and with NAR and healthy chil-
dren. However, only 3 studies with patients with NAR
were available.
This systematic review supports the argument that
atopy and rhinitis should be considered for the clinical
interpretation of FeNO measurements. In fact, adults
with allergic rhinitis and children with atopy (those pre-
senting higher FeNO levels) may have FeNO measure-
ments out of the ‘normal’ range previously proposed
that do not take in account both atopy and rhinitis. To
allow a visual representation of comparisons between
groups we present the illustration in Figure 2[20,21].
Our study has some limitations. The interpretation of
quantitative synthesis of data was not possible. FeNO
values were presented in different ways (e.g. different
s u m m a r ya n dd i s p e r s i o nm e a s u r e s )( T a b l e2 )s oo n l y2
to 3 articles could be used for each comparison. More-
over, a high heterogeneity was observed (Additional File
2, Figure S1-S3). Despite our best efforts, we had no
access to the values of FeNO in four studies. These arti-
cles were included on the review, allowing a broad qua-
litative assessment of published studies but could not be
used in the meta-analysis.
The methods of the included studies were highly vari-
able. There were variations in the definitions of atopy,
rhinitis and healthy individuals. The definition of healthy
individuals was particularly variable, often incomplete
and sometimes missing. Also, various settings, eligibility
criteria and sample sizes were used. In some of the stu-
dies with children [8,12,21-23] the age range was too
broad (> 5 years). FeNO in children is strongly asso-
ciated with age and body size [5]. The inclusion criteria
regarding smoking status were different and many did
not report the smoking status (Additional File 1, Table
S1). As smoking [9,24-26], and passive smoking [27],
can interfere with FeNO values, not accounting for the
smoking status may be one of the reasons for the differ-
ences observed between the studies. Moreover, most
studies presented only univariate analysis, with few mul-
tivariate models reported. Multivariate models could
consider additional personal characteristics (e.g. height,
age or gender).
Future studies should report adequate summary and
dispersion measures, allowing for further quantitative
synthesis. Samples sizes and subjects characteristics
should be accurately described. Moreover, the factors
that are known to modify FeNO should be taken into
account. It is also important to follow current recom-
mendations on FENO measurement [6].
In conclusion, FeNO values are higher in individuals
with rhinitis and/or atopy without other diseases. These
effects are small, seem to be independent and should be
further studied using multivariate models. The causes
for the effects of atopy and rhinitis on FENO values also
need further study. The effect of atopy was observed
only in children. The combined effect of atopy and rhi-
nitis produced higher FeNO values in adults. These
results support that atopy and rhinitis should be consid-
ered when interpreting or when defining FeNO refer-
ence values.
Additional material
Additional file 1: Tables with information on characteristics of the
included studies and their samples. Table S1. Studies’ characteristics
regarding country, smoking habits FeNO equipment used and study
design; Table S2. Definitions of healthy groups and number of
participants per group in included studies.
Additional file 2: meta-analysis comparing FeNO values in atopic
and healthy children; in allergic rhinitis and healthy adults; and in
allergic rhinitis and healthy children. Figure S1. Meta-analysis of
studies comparing FeNO values in Atopic and Healthy children; Figure
S2. Meta-analysis of studies comparing FeNO values in Allergic Rhinitis
and Healthy adults; Figure S3. Meta-analysis of studies comparing FeNO
values in Allergic Rhinitis and Healthy children.
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